Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 in Autoimmune Bullous Disease
NCT06900010Phase 2Recruiting
- Sponsor
- Shandong First Medical University
- Start
- Apr 2025
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of gamgertamig in autoimmune bullous disease (AIBD), sponsored by Shandong First Medical University. Started Apr 2025; status: recruiting.
02
Drugs
gamgertamig
03
Conditions
autoimmune bullous disease (AIBD)
Beyond the preview
Go deeper on NCT06900010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06900010.